Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

Pincus T(2003)An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20 % response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial Arthritis Rheum. 48 625-30

Strand V(2004)Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus Arthritis Rheum. 50 2858-68

Koch G(2000)Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum. 2000;43:506–14. A published erratum appears in Arthritis Rheum 43 1345-7

Amara I(2006)Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance Health Qual Life Outcomes 4 79-47

Crawford B(2000)Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index Rheumatology (Oxford) 39 321-9

Wolfe F(2008)RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories J Rheumatol. 35 2136-40

Petri MA(2000)Clinical quality management in rheumatoid arthritis: putting theory into practice Rheumatology (Oxford) 39 542-14

Mease PJ(1993)The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials Arthritis Rheum. 36 729-24

Merrill JT(2012)Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study Rheumatology (Oxford) 51 2204-86

Lahita RG(1988)The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum. 31 315-21

Pincus T(2003)An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20 % response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial Arthritis Rheum. 48 625-30

Strand V(2004)Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus Arthritis Rheum. 50 2858-68

Koch G(2000)Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum. 2000;43:506–14. A published erratum appears in Arthritis Rheum 43 1345-7

Amara I(2006)Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance Health Qual Life Outcomes 4 79-47

Crawford B(2000)Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index Rheumatology (Oxford) 39 321-9

Wolfe F(2008)RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories J Rheumatol. 35 2136-40

Petri MA(2000)Clinical quality management in rheumatoid arthritis: putting theory into practice Rheumatology (Oxford) 39 542-14

Mease PJ(1993)The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials Arthritis Rheum. 36 729-24

Merrill JT(2012)Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study Rheumatology (Oxford) 51 2204-86

Lahita RG(1988)The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum. 31 315-21